EGFR and non-small cell lung carcinoma: A phase II study demonstrated that the combination of a MET inhibitor (capmatinib) with a programmed cell death 1 inhibitor (nivolumab) showed promising antitumor activity and a manageable safety profile in patients with advanced NSCLC with EGFR WT and unscreened programmed cell death ligand 1 (77).